The Science of Stacking: How Researchers Combine Peptides for Synergistic Effects
Why researchers combine peptides, how the pairings are chosen, and what the studies say about compounds working together.
From ReVia
In pharmaceutical research, combination therapy is a well-established principle: sometimes two compounds working together achieve effects that neither can accomplish alone. The same logic drives peptide stacking in research settings — and the science behind it is more rigorous than you might expect.
Why Stack? The Logic of Synergy
Biological systems are complex networks, not linear pathways. A single peptide targeting a single receptor can produce meaningful effects, but combining peptides that target complementary pathways can create synergistic outcomes. This isn't just additive — true synergy means the combined effect exceeds what you'd predict from each compound individually.
Classic Research Combinations
Several peptide combinations have become standards in the research community, supported by published literature and established research protocols:
- BPC-157 + TB-500: Perhaps the most studied combination. BPC-157's local tissue effects (angiogenesis, growth factor modulation) complement TB-500's systemic activity (actin regulation, cell migration).
- CJC-1295 + Ipamorelin: Researchers studying growth hormone secretion frequently combine a GHRH analog with a ghrelin mimetic. The two pathways converge on GH release through different mechanisms, potentially producing a more physiological secretion pattern.
Research Use Only (RUO): The information presented in this library summarizes published scientific research and is provided for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment recommendations. All compounds referenced carry a Research Use Only designation and are intended for laboratory research use only.